Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors

World Journal of Gastroenterology

Volumn 18, Issue 20, 2012, Pages 2569-2575

  Jiang, Jing ^a   Jin, Mei Shan ^a   Suo, Jian ^a   Wang, Yin Ping ^a   He, Liang ^a   Cao, Xue Yuan ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

p53; Epidermal growth factor receptor; Gastrointestinal stromal tumor; Ki 67 alteration; Prognosis

Indexed keywords

ANTIBODY; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; KI 67 ANTIGEN; PROTEIN P53; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONSENSUS SEQUENCE; CORRELATIONAL STUDY; COX 2 GENE; DISEASE SPECIFIC SURVIVAL; EGFR GENE; EVALUATION STUDY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KI67 GENE; MAJOR CLINICAL STUDY; MALE; MITOSIS RATE; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; AGED; CANCER GRADING; GASTROINTESTINAL TUMOR; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MITOSIS INDEX; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE 2; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOTIC INDEX; NEOPLASM GRADING; PIPERAZINES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84871888257     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i20.2569     Document Type: Article

References (31)

1. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007; 369: 1731-1741
2. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Gallina G, Marzotto A, Sartor C, Barbareschi M, Cantaloni C, Messerini L, Bearzi I, Arrigoni G, Mazzoleni G, Fletcher JA, Casali PG, Talamini R, Maestro R, Dei Tos AP. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol 2010; 34: 1480-1491
3. Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005; 103: 821-829
4. Andersson J, Bümming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joensuu H, Odén A, Gustavsson B, Kindblom LG, Nilsson B. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 2006; 130: 1573-1581
5. Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 2009; 33: 437-446
6. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009; 33: 1401-1408
7. Kang YN, Jung HR, Hwang I. Clinicopathological and immunohistochemical features of gastointestinal stromal tumors. Cancer Res Treat 2010; 42: 135-143
8. Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, Imamura M, Yamada T, Nawata H, Tsuneyoshi M. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 2005; 36: 828-837
9. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411-1419
10. Dorn J, Spatz H, Schmieder M, Barth TF, Blatz A, Henne-Bruns D, Knippschild U, Kramer K. Cyclin H expression is increased in GIST with very-high risk of malignancy. BMC Cancer 2010; 10: 350
11. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, McClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566-578
12. Song Z, Wang JL, Pan YL, Tao DY, Gan MF, Huang KE. Survival and prognostic factors analysis in surgically resected gastrointestinal stromal tumor patients. Hepatogastroenterology 2009; 56: 149-153
13. Ruiz-Tovar J, Diez-Tabernilla M, Housari G, Martinez-Molina E, Sanjuanbenito A. Gastrointestinal stromal tumors: actin expression, a new prognostic factor? Am Surg 2010; 76: 1244-1250
14. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29: 52-68
15. Di Vizio D, Demichelis F, Simonetti S, Pettinato G, Terracciano L, Tornillo L, Freeman MR, Insabato L. Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours. BMC Cancer 2008; 8: 134
16. Meara RS, Cangiarella J, Simsir A, Horton D, Eltoum I, Chhieng DC. Prediction of aggressiveness of gastrointestinal stromal tumours based on immunostaining with bcl-2, Ki-67 and p53. Cytopathology 2007; 18: 283-289
17. Nakagawa M, Nabeshima K, Asano S, Hamasaki M, Uesugi N, Tani H, Yamashita Y, Iwasaki H. Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands. Cancer Sci 2009; 100: 654-662
18. Gumurdulu D, Erdogan S, Kayaselcuk F, Seydaoglu G, Parsak CK, Demircan O, Tuncer I. Expression of COX-2, PCNA, Ki-67 and p53 in gastrointestinal stromal tumors and its relationship with histopathological parameters. World J Gastroenterol 2007; 13: 426-431
19. Fux R, Schwab M, Thon KP, Gleiter CH, Fritz P. Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res 2005; 11: 4754-4760
20. Huang HY, Huang WW, Lin CN, Eng HL, Li SH, Li CF, Lu D, Yu SC, Hsiung CY. Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol 2006; 13: 1633-1644
21. Konsti J, Lundin M, Joensuu H, Lehtimäki T, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Sailas L, Isola J, Lundin J. Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol 2011; 11: 3
22. Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, Sciot R, Blay JY, Hogendoorn PC. Cell cycle/ apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2009; 15: 4191-4198
23. Gunji Y, Nikaidou T, Okazumi S, Matsubara H, Shimada H, Nabeya Y, Aoki T, Makino H, Miyazaki S, Ochiai T. Evaluation of Ki-67 and p53 expression in primary and repeated liver metastases of GISTs. Hepatogastroenterology 2005; 52: 829-832
24. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137: 413-431
25. Hata Y, Ishigami S, Natsugoe S, Nakajo A, Okumura H, Miyazono F, Matsumoto M, Hokita S, Aikou T. P53 and MIB-1 expression in gastrointestinal stromal tumor (GIST) of the stomach. Hepatogastroenterology 2006; 53: 613-615
26. Cai YC, Jiang Z, Vittimberga F, Xu X, Savas L, Woda B, Callery M, Banner B. Expression of transforming growth factoralpha and epidermal growth factor receptor in gastrointestinal stromal tumours. Virchows Arch 1999; 435: 112-115
27. Chan AT. COX-2 expression in adenoma: an imperfect marker for chemoprevention. Gut 2010; 59: 568-569
28. Wu WK, Sung JJ, Lee CW, Yu J, Cho CH. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett 2010; 295: 7-16
29. Spugnini EP, Porrello A, Citro G, Baldi A. COX-2 overexpression in canine tumors: potential therapeutic targets in oncology. Histol Histopathol 2005; 20: 1309-1312
30. Miao R, Liu N, Wang Y, Li L, Yu X, Jiang Y, Li J. Coexpression of cyclooxygenase-2 and vascular endothelial growth factor in gastrointestinal stromal tumor: possible relations to pathological parameters and clinical behavior. Hepatogastroenterology 2008; 55: 2012-2015
31. Sevinc A, Camci C, Sari I, Kalender ME, Er O, Soyuer I, Dikilitas M, Yilmaz U, Sagol O, Alacacioglu A. Cyclooxygenase-2 expression in gastrointestinal stromal tumours. Asian Pac J Cancer Prev 2010; 11: 849-853